T1	Participants 482 575	Thirty nonbleeding patients with international normalized ratios (INRs) ranging from 6.0-10.0
T2	Participants 1515 1559	asymptomatic patients with INRs of 6.0-10.0.
T3	Participants 1606 1640	patients at high risk for bleeding
